Two children with HIV who were treated immediately after birth have no signs of the virus 9 and 23 months later, scientists said in a report that suggests a potential approach to curing HIV-infected babies.
A diabetes pill developed by Eli Lilly & Co. and Boehringer Ingelheim GmbH was rejected by U.S. regulators because of previously disclosed manufacturing deficiencies at a German plant that hadn’t been resolved.
Boehringer Ingelheim GmbH didn’t disclose a data analysis to U.S. regulators that indicated the blood-thinner Pradaxa may have caused more fatal bleeding after it was cleared for sale than the drug did in a study used to win approval, unsealed court filings show.
InterMune Inc., the developer of a medicine for idiopathic pulmonary fibrosis, dropped the most in almost two years as investors grew concerned about competition from drugmaker Boehringer Ingelheim GmbH.
Boehringer Ingelheim GmbH Chairman Andreas Barner may use product deals and regional acquisitions to fuel growth as the world’s largest family-owned drugmaker faces competition from lower-priced generics.
Evotec AG rose the most in almost two weeks after saying it received a payment of 1.5 million euros ($1.93 million) for achieving a research milestone under an agreement with Boehringer Ingelheim GmbH.
Boehringer Ingelheim GmbH, the German family-owned drugmaker, withheld or failed to preserve “countless” files sought by patients suing over the company’s blood thinner Pradaxa and must pay a fine of almost $1 million, a judge ruled.